Business


drugs, and by extension the companies behind them, can further leverage working in true partnerships for the benefit of suffering patients.


DDW


Dr Swati Prasad is Director, Alliance Management at Charles River Laboratories. She leads and man- ages strategic partnerships and drug development alliances with bottom-line focus on profitability, visibility and sustainability. Previously, she was at AstraZeneca Pharmaceuticals where she managed external collaborations and partnerships. She has expertise in collaboration management and is a certified project management professional (PMP). She has extensive experience in large pharma, CRO and life science industry with hands-on drug development experience across diverse therapeutic areas and entire lifecycle, from preclinical research to clinical development candidates. She holds a doctorate degree in Chemistry from Tata Institute of Fundamental Research, India, an MBA from Wilmington University and a bachelors in Classical Music from Prayag Sangeet Samiti, India.


Mary Lou Bell is Vice President, Program & Alliance Management and a member of the Exec Team at Nimbus. She has 25 years of experience in portfolio and project management, alliance man- agement and drug development. Prior to joining Nimbus, Mary Lou was Vice President of Program & Alliance Management at Anchor Therapeutics. As a Director in Project Management at Wyeth and then Pfizer, Mary Lou has directed pro- grammes from discovery through all phases of clin- ical research and regulatory interactions, to regis- tration/launch/early commercialisation. Her drug development experience includes drugs, biologics and combination products. She has directed many alliances (in-licences, out-licences, R&D and com- mercial collaborations, patient advocacy groups) among small companies and large corporations in the US, Europe and Japan. Mary Lou and the teams she led have achieved registration approvals in the US and ex-US, and significantly contributed to alliance partner registration approvals in the US and other territories. Mary Lou began her career at Genetics Institute.


Dr Charles McOsker is Senior Vice President, Technical Operations at BioMotiv LLC. He has more than 30 years of experience in both the phar- maceutical and biotechnology industries. He brings an extensive background in the manage- ment of multifunctional teams in drug discovery and development to his role as Senior Vice


30 Drug Discovery World Winter 2017/18


President of Technical Operations with BioMotiv. Prior to joining BioMotiv in 2012, Dr McOsker founded Airway Therapeutics, a biotechnology company created to develop promising therapeu- tics arising from the pulmonary research pro- gramme of Cincinnati Children’s Hospital Medical Center. At Airway Therapeutics, Dr McOsker suc- cessfully managed the early stages of the compa- ny’s technology development and fundraising. Previously, Dr McOsker served as Director of Business Development for the Drug Discovery Center at the University of Cincinnati where he was responsible for negotiating agreements with a potential value to the University of more than $30 million. Dr McOsker began his career at Procter & Gamble Pharmaceuticals. Over the course of 23 years he held numerous management positions in drug discovery and development and was responsi- ble for teams that discovered two products that successfully entered late-stage clinical develop- ment. Dr McOsker received his undergraduate degree in chemistry at Hope College in Michigan and his PhD in biochemistry and molecular biolo- gy at Cornell University.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72